The Traderszone Network

Published in TZ Latest News 9 November, 2021 by The TZ Newswire Staff

SCYNEXIS Announces Successful Completion of Phase 1 Trial Evaluating Intravenous (IV) Formulation of Ibrexafungerp

Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple ascending dose (MAD) study Safety and tolerability of new liposomal IV formulation confirmed to reach target exposure in single ascending dose (SAD) and multiple ascending dose (MAD) study